Ahmedabad, Oct 22 (UNI) Zydus Cadila reported a consolidated income of Rs 741 crore in the second quarter, ended September 30, 2008, up by 22 per cent from Rs 610 crore in the corresponding quarter of the previous year.
The operating net profit was up by 33 per cent at Rs 108 crore compared to Rs 82 crore in the second quarter last year.
During the quarter, the Company's subsidiaries in France and US registered a strong performance. Zydus France SAS, which currently markets over 120 generic presentations, registered 27 per cent growth in sales. The Company also received approvals for six dossiers for new products and three site transfer applications from the French regulatory authority AFSSAPS during the quarter.
In the US, the Company's sales grew by 28 per cent and it also received approvals from the USFDA for Bromocriptine Mesylate Capsules and Ramipril Capsules.
The group filed five additional DMFs and three more ANDAs this quarter taking the total to 64 DMFs and 79 ANDA filings, of which 41 have been approved so far.
It also entered into an agreement with WHO to explore a possible collaboration in the development of a cocktail for the treatment of rabies, through the use of monoclonal antibodies (MAbs).
UNI PVN RN VKG1540